Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team

Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands
Clinical Operations Team

NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,
Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D.,
Ph.D., MBA, to the position of Executive Vice President and Chief Medical
Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the
clinical development of Achillion's portfolio of compounds to treat HCV.

In addition, Achillion also announced today the expansion of its clinical
operations group with the recent addition of Kevin Kucharski, formerly head of
clinical operations at Pharmasset, who will serve as Senior Vice President of
Clinical Operations.

"We are delighted that David is bringing his wealth of hepatitis and drug
development expertise to Achillion. His operational and regulatory experience,
highlighted by the regulatory approval of antivirals such as interferon
alpha-2b/ribavirin and entecavir, will greatly benefit Achillion as we
accelerate our development plans and seek to initiate registrational studies
with sovaprevir and ACH-3102 during the latter part of next year," commented
Michael D. Kishbauch, President and Chief Executive Officer of Achillion.

Dr. Apelian commented, "It is a very exciting time for me to be joining
Achillion as Chief Medical Officer, and I look forward to further accelerating
the development of the all-oral, interferon-free regimens containing
sovaprevir and ACH-3102 for the treatment of chronic HCV."

Mr. Kishbauch also stated, "As Achillion continues its maturation into a
late-stage biopharmaceutical company, the addition of both Kevin and David
will expand our bandwidth, providing critical expertise and the support
necessary for our HCV clinical development programs and our planned Phase 3
development."

David Apelian, M.D., Ph.D., MBA

Dr. Apelian brings to Achillion more than 13 years of industry experience from
Bristol-Myers Squibb, Schering Plough and GlobeImmune where he focused on
hepatology and infectious disease clinical development. Dr. Apelian was
Clinical Director in the Infectious Diseases Group at Bristol-Myers Squibb
(BMS), serving as medical co-lead for the clinical development and NDA
submission of entecavir for chronic hepatitis B viral infection (HBV). Prior
to BMS, Dr. Apelian served as Clinical Director in the Department of
Hepatology/Gastroenterology at Schering Plough, coordinating a supplemental
NDA filing for interferon alpha-2b and ribavirin for the treatment of
pediatric patients with chronic hepatitis C viral infection (HCV). Most
recently, Dr. Apelian served as Senior Vice President of Research and
Development and Chief Medical Officer at GlobeImmune, where he was responsible
for clinical development, regulatory affairs, clinical immunology, development
of companion diagnostics, as well as target discovery and preclinical
research.

Dr. Apelian completed his residency training in Pediatrics at New York
Hospital, Cornell Medical Center. He received his M.D. from the University of
Medicine and Dentistry of New Jersey, and his Ph.D. in Biochemistry and B.A.
from Rutgers University. He also holds an M.B.A. from Quinnipiac University

Kevin Kucharski

Mr. Kucharski comes to Achillion with more than two decades of clinical
operations expertise, with a focus on conducting U.S. and global clinical
trials, ranging from Phase 1 through Phase 4. Prior to joining Achillion, Mr.
Kucharski was Vice President of Clinical Operations at Pharmasset since 2007,
and then at Gilead Sciences following their acquisition of Pharmasset. While
at Pharmasset, Mr. Kucharski provided effective oversight and execution of
various global clinical development projects including PSI-7977 and PSI-938.
Prior to Pharmasset, Mr. Kucharski was Senior Director of Clinical Operations
at Altana Pharma US, a Nycomed Company, where he established the Clinical
Operations group. Prior to that, Mr. Kucharski held positions of increasing
responsibility in Clinical Operations at Schering-Plough Research Institute.
Mr. Kucharski was awarded his B.S. in Biology Research from the University of
Scranton.

About HCV

The hepatitis C virus is the most common cause of viral hepatitis, which is an
inflammation of the liver. It is currently estimated that more than 170
million people are infected with HCV worldwide including more than 5 million
people in the United States, more than twice as widespread as HIV.
Three-fourths of the HCV patient population is undiagnosed; it is a silent
epidemic and a major global health threat. Chronic hepatitis, if left
untreated, can lead to permanent liver damage that can result in the
development of liver cancer, liver failure or death. Few therapeutic options
currently exist for the treatment of HCV infection. The current standard of
care is limited by its specificity for certain types of HCV, significant
side-effect profile, and injectable route of administration.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing
important new treatments to patients with infectious disease. Achillion's
proven discovery and development teams have advanced multiple product
candidates with novel mechanisms of action. Achillion is focused on solutions
for the most challenging problems in infectious disease, including HCV and
resistant bacterial infections. For more information on Achillion
Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to
risks, uncertainties and other important factors that could cause actual
results to differ materially from those indicated by such forward-looking
statements, including statements with respect to: the potency, safety,
tolerability, effectiveness and other characteristics of sovaprevir and
ACH-3102; Achillion's expectations regarding timing for the commencement,
completion and reporting of results of its -007 clinical trial of sovaprevir
and ACH-3102 in combination with ribavirin, as well as with respect to the
advancement into later stages of its clinical studies; and the expected
contributions of Dr. Apelian and Mr. Kucharski and the planned expansion of
the clinical operations group. Among the factors that could cause actual
results to differ materially from those indicated by such forward-looking
statements are risks relating to, among other things Achillion's ability to:
replicate in later clinical trials positive results found in earlier stage
clinical trials of sovaprevir, ACH-3102 and its other product candidates;
advance the development of its drug candidates under the timelines it
anticipates in current and future clinical trials; obtain necessary regulatory
approvals; obtain patent protection for its drug candidates and the freedom to
operate under third party intellectual property; establish commercial
manufacturing arrangements; identify, enter into and maintain collaboration
agreements with appropriate third-parties; compete successfully with other
companies that are seeking to develop improved therapies for the treatment of
HCV; manage expenses; successfully execute on its business plans and
strategies; and raise the substantial additional capital needed to achieve its
business objectives. These and other risks are described in the reports filed
by Achillion with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and its
subsequent SEC filings.

In addition, any forward-looking statement in this press release represents
Achillion's views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date. Achillion
disclaims any obligation to update any forward-looking statement, except as
required by applicable law.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         gschulman@achillion.com
        
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com
        
         Media:
         Sally Barton
         Ogilvy PR
         Tel. (212)880-5240
         sally.barton@ogilvy.com
        
         Investors:
         Seth Lewis
         The Trout Group, LLC
         Tel. (646) 378-2952
         slewis@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.